 |
| Global Trigeminal Neuralgia Treatment Market Growth |
Trigeminal neuralgia treatment involves the management of trigeminal neuralgia
disorder through medication management and surgical procedures. Trigeminal
neuralgia, also known as tic douloureux, is a chronic pain condition that
affects the trigeminal or 5th cranial nerve, which carries sensation from the
face to the brain. The condition causes episodes of sharp, electric shock-like
pains in areas of the face when a person performs everyday activities such as
eating, talking, and brushing teeth. There is no cure for trigeminal neuralgia,
and treatment aims to manage disorder effectively to help people lead normal
lives.
The global
trigeminal neuralgia treatment market is estimated to be valued at US$ 242.95
million in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as highlighted
in a new report published by Coherent Market Insights.
Market key trends:
The key trend propelling the growth of trigeminal neuralgia treatment market is
the increasing prevalence of trigeminal neuralgia disorder globally. According
to the Trigeminal Neuralgia Association, approximately 200,000 people are
impacted by trigeminal neuralgia condition in the United States every year. The
growing geriatric population is further fueling the prevalence of the disorder
as it primarily manifests in people aged above 40 years. With increasing
longevity, the median age cases of TN disorder is increasing, thereby driving
the demand for effective trigeminal neuralgia treatment options such as
medication therapy and surgery.
Segment
Analysis
The global trigeminal neuralgia treatment market is segmented into drug class,
route of administration, distribution channel, and geography. Based on drug
class, the market is segmented into anti-seizures, antidepressants, anticonvulsants,
and others. Among these, anticonvulsants hold the largest share of around 60%
as they are dominating treatment for trigeminal neuralgia. Anticonvulsants like
carbamazepine are highly effective and first line of treatment for managing
pain associated with trigeminal neuralgia.
Key Takeaways
Global
Trigeminal Neuralgia Treatment Market Growth is expected to witness
high growth at a CAGR of 7.5% during
the forecast period of 2023 to 2030. The market size for 2024 is US$ 242.95 Mn.
Regional analysis: North America dominates the global trigeminal neuralgia
treatment market and is expected to grow at a high rate during the forecast
period. This is attributed to the growing awareness about trigeminal neuralgia
treatments and advanced healthcare infrastructure in countries like the US and
Canada. The availability of major key players and early approval of new drugs
in the region also supports market growth.
Key players analysis: Key players operating in the trigeminal neuralgia
treatment market are F. Hoffmann-La Roche Ltd. (Switzerland), Teva
Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.),
GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson &
Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India),
Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Abbott
(U.S.), Hikma Pharmaceuticals PLC (U.K.), Allergan (Ireland), Eli Lilly and
Company (U.S.), Aurobindo Pharma (India), Lupin (India), SHIONOGI & Co.,
Ltd. (Japan), AbbVie Inc. (U.S.). Major players are focused on developing new
drugs and expanding geographically to strengthen their market position.
Get More Insights On This Topic: https://www.newsanalyticspro.com/global-trigeminal-neuralgia-treatment-market-scope/